Activation of EGFR and its downstream pathways is a significant event in the formation of pancreatic ductal adenocarcinoma (PDAC), reinforcing ERK pathway activation to promote tumor transformation after the initial driver mutation(s) occur in KRAS [2]. The gene discussed is EGFR; the disease is pancreatic ductal adenocarcinoma.